Corporate Overview
Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNAi (RNA interference) to precisely target and silence disease-associated genes. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence is using its proprietary mRNAi GOLD™ platform to advance a growing pipeline of both wholly owned programs and partnership programs for diseases with high unmet need. The company's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare iron-loading anemia conditions. Silence maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt and Takeda, among others.